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ABSTRACT 
 
The mucopolysaccharidoses (MPSs) are a group of lysosomal storage diseases (LSDs) 
which are characterized by the aberrant primary storage of glycosaminoglycans (GAGs) in 
lysosomes of multiple organ and tissue systems. The most commonly diagnosed is MPS Type 
I (MPS I), caused by mutations in the gene which codes for α-L-iduronidase (IDUA). 
Biochemically, MPS I is characterized by the aberrant primary lysosomal storage of 
incompletely degraded dermatan and heparan sulfates, along with a secondary accumulation 
of gangliosides and other compounds in lysosomes. Its clinical manifestation in severe form 
leads to early death, characterized by progressive central nervous system disease (with 
behavioral and cognitive impairment), severe bone and joint abnormalities, respiratory and 
cardiac impairment, hepatosplenomegaly, coarse facies and corneal clouding. There are three 
recognized diagnostic clinical categories of MPS I: Hurler (severe), Hurler-Scheie 
(intermediate) and Scheie (attenuated) across differing levels of IDUA activity. Treatment 
strategies addressing the etiological cause include the restoration of enzyme activity and 
substrate deprivation, while symptomatic therapy involves management of secondary 
immunological effects and surgical amelioration of symptoms. Animal models of the disease 
have been integral to understanding pathology, disease progression, and the development of 
treatments. 
To explore the impact of secondary accumulating products in the pathology of 
neuronopathic MPS diseases, Mohammed et al. (2012) created double knockout mouse models 
of MPS IIIA and IIIB (which also exhibit primary storage of heparan sulfate) and β-1,4-N-
acetylgalactosaminyltransferase (B4galnt1, henceforth referred to as GalNAcT) deficiency – 
an enzyme responsible for the synthesis of complex gangliosides. The double knockouts 
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exhibited an accelerated progression of the disease and a severely shortened lifespan. The aim 
of this project was to find out if such an accelerated neuropathology is also seen in MPS 
I/GalNAcT double knockout mice and to characterize MPS I neuropathology in an animal 
model with accelerated CNS pathology.  
Single knockout (SKO) mice for GalNAcT deficiency and MPS I obtained from the 
labs of Dr. Mark Sands (Washington University in St. Louis, MO) and Dr. Ron Schnaar (Johns 
Hopkins University in Baltimore, MD) respectively on a C57BL/6J background were bred in 
order to generate double knockout mice and their age-matched single knockout and normal 
controls. At 4 months of age, the double knockout showed an accelerated clinical phenotype 
and noticeable impairment in motor coordination, gait and body condition compared to the 
single knockouts and unaffected controls.  
Our findings so far show an accelerated progression of pathology in the double 
knockout compared to the single knockout mouse based on the observed clinical signs and 
gross observations on dissection. Future work will involve obtaining more double knockouts 
and conducting a thorough comparative biochemical, histological, and behavioral analysis to 
achieve statistically significant results. Such double knockout mice may provide a better 
understanding of the neuropathology of the disease and be useful in rapid testing of therapeutic 
strategies. 
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CHAPTER 1: LITERATURE REVIEW 
The lysosomal storage diseases are a group of about 50 inherited metabolic diseases 
which are caused in the majority of cases by deficient activity of lysosomal enzymes, resulting 
in the accumulation of incompletely degraded substrates in the lysosomes [4]. Of these, the 
MPS diseases are characterized by the primary storage GAGs. There are several different MPS 
disorders, categorized based on both the enzyme deficiencies and primary GAGs stored [2]. 
While treatments do exist, such as hematopoietic stem cell therapy (HSCT) and enzyme 
replacement therapy (ERT), there are none which can ensure complete arrest of clinical disease 
pathology. It is therefore vital, to gain a better understanding about the pathophysiology of 
these diseases, their rate limiting factors and prospective therapeutic strategies. 
Endosomal-Lysosomal Vesicle Trafficking Pathway 
In animal cells, the lysosomes are responsible for degradation of biomolecules, 
signaling pathways, plasma membrane maintenance, and autophagy. These functions involve 
the endosomal-lysosomal pathway, a cascading system of vesicles transported from the plasma 
membrane to the lysosomes across a basic-to-acidic pH gradient (6.5-4.5) compared to the pH 
of the cytoplasm (~7.0) caused by acidification of the endosomes by ATP-proton-pumps. The 
first step to the pathway is the binding of a ligand or communication signal to a specific 
receptor on the plasma membrane. This initiates the formation of an endocytic vesicle as the 
plasma membrane internalizes the receptor-signaling molecule complex that is trafficked 
across the cytoplasm by membrane association proteins, particularly the Rab family of 
GTPases.  The next step is the formation of a sorting endosome, a vesicle that segregates the 
molecules to be recycled back to the plasma membrane, those which need to be returned to the 
11 
 
trans-golgi network (TGN) via a retromer and those which need to be degraded in the 
lysosomes. 
 
The latter constitute the next step of the endocytic pathway – the formation of a mature 
or late endosome, a step which occurs concurrently as more and more endocytic vesicles are 
formed. Endosomal trafficking and sorting is regulated by the Rab family of GTPases. The 
endosomes are transported across the TGN by the mannose-6-phosphate ligand, which binds 
the biomolecules to be degraded with its receptor, forming clatherin-coated vesicles that 
ultimately fuse with the lysosomes with the help of calmodulin-mediated Ca2+ ions [3]. Once 
in the lysosomes, acid hydrolases catalyze step-wise degradation of substrates. However, a 
Figure 1.1 The endosomal-lysosomal pathway is an internal 
vesicular transport system which internalizes complex 
substrates for degradation in the lysosomes while recycling 
other components (such as receptors) back to the cell surface. 
[3] 
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deficiency in the activity of any one of these enzymes can lead to the accumulation of its 
corresponding substrate, thus causing a lysosomal storage disease. 
Lysosomal Storage Diseases 
 
A lysosomal storage disease (LSD) is a progressive, multi-system inborn metabolic 
disorder which occurs in the majority of cases due to the reduction or absence of activity of a 
specific enzyme responsible for degrading particular macromolecules. All LSDs have certain 
characteristics in common: The accumulation of one or more types of incompletely catabolized 
compounds in the lysosomes; the deficiency of activity of critical lysosomal associated 
proteins, an enzyme or important co-factor related to the degradation of a primary storage 
substrate; and the appearance of vacuolized bodies in the cytoplasm exhibiting said substrate(s) 
[4]. 
The clinical manifestations of LSDs may include enlargement of multiple organs (such 
as the liver and the spleen), central and peripheral nervous system disease, bone and joint 
abnormalities, and pre-mature death. Each LSD is distinct, based on the defective gene. 
Furthermore, within some specific LSDs, different levels of clinical severity and progression 
are seen based on the presence and degree of any residual enzyme activity or other specific 
effects of the mutation. Although the lysosome was discovered in the mid-20th century (de 
Duve [5],  LSDs were described clinically beginning in the mid-19th century. They are rare 
genetic diseases; each LSD has different incidence rates in different parts of the world. The 
aggregate estimated occurrence of all LSDs is approximately 1 in every 7000 births. They 
follow a Mendelian inheritance pattern which is commonly autosomal recessive, though some 
are X-linked [6].   
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Although no standardized method of classification exists for the approximately 50 
LSDs discovered so far, one approach is to classify them based on the type of primary substrate 
stored (Lipid storage disorders, glycoproteinoses, mucopolysaccharidoses, mucolipidoses, 
etc.). Many of these disorders are also eponymously named for those who first characterized 
them (e.g. Tay-Sachs disease, Fabry disease, Gaucher’s disease, etc.). Another approach to 
classification involves one based on the nature of the defect and/or the type of protein affected 
(lysosomal enzymes, membrane transport proteins, post-translational modifiers of enzymes, 
soluble proteins, transmembrane proteins and proteins which are enzyme or substrate 
protecting in nature) [4]. The major categories of LSDs based on primary accumulating 
substrates are shown in Figure 1.1. 
The Mucopolysaccharidoses 
The MPSs are characterized by the primary lysosomal storage of GAGs. Except for the 
X-linked Hunter syndrome (MPS II), all the MPSs are autosomal recessive by inheritance. 
Each has its own specific enzyme defect (11 have been identified so far) and the major types 
of MPS diseases are distinguished by the inheritance pattern, clinical signs, and the GAGs that 
are primarily stored. It is important to understand GAG structure and metabolism as well as 
the enzymes necessary for their degradation processes to biochemically classify these diseases 
[2]. They are long unbranched heteropolysaccharide chains which consist of repeating 
disaccharide units of an amino sugar and a urionic sugar (except keratan sulfate which has d-
galactose instead of the latter). The major GAGs in the body are chondroitin sulfate (CS), 
dermatan sulfate (DS), keratan sulfate (KS), heparan sulfate (HS), hyaluronic acid/hyaluronan 
(HA), and heparin.  
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Figure 1.2 Classification of Lysosomal Storage Diseases based on primary storage substrate 
[2]. 
Each has its own localization, structure and function. The most prevalent GAG 
throughout the body is chondroitin sulfate. It is a major component of complex proteoglycans 
and the extracellular matrix (ECM). Its major area of localization is cartilage and bones, where 
it provides support and lubrication. Keratan sulfate was first localized in the cornea but it is 
also seen in proteoglycans associated with chondroitin sulfate. Heparan sulfate is present on 
the plasma and basal membranes. Dermatan sulfate is located across multiple organ systems 
with epithelial tissue while hyaluronan is principally found in synovial fluid, articular cartilage 
and the ECM. In general, GAGs are commonly located in both the plasma membrane and 
extracellular proteoglycans, attached by an O-glycoside bond at galactose-galactose-xylose 
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branches, the heavily glycosylated protein ‘spine’ seen in extracellular proteoglycans and have 
important functions in the maintenance of connective tissue.  
 
Figure 1.3 Degradation pathways and associated enzymes for various GAGs, refer KEGG 
Pathway, map00531 
 
The degradation of GAGs involves multiple enzymes (Figure 1.3) working in 
cascading processes inside the lysosomes. A deficiency in any of the enzymes causes 
incomplete degradation of particular GAGs causing them to be stored aberrantly in the cells of 
multiple organ and tissue systems leading to MPS. These diseases manifest clinically in two 
major areas of pathology: the central nervous system and/or bone and connective tissue. 
Collectively, MPSs I, II, IIIA, IIIB, IIIC, IIID and VII show progressive CNS disease and have 
a notable biochemical feature in common: they exhibit HS as one of their primary storage 
products in the lysosomes. In addition, some MPS diseases also exhibit a secondary storage of 
gangliosides and other compounds which may contribute to their neuropathology [4, 7]. 
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History and clinical characteristics 
The MPS diseases were first discovered in 1917, when Dr. Charles Hunter first 
described what came to be known as MPS II (deficiency of iduronate-2-sulfatase, coded by the 
IDS gene) [8]. The patients were 8 and 10 years of age respectively, showed signs cognitive 
and developmental impairment and dysostosis multiplex, which is an overall skeletal and joint 
dysmorphia. Now, it is well known that MPS II patients suffer a wide range of symptoms 
including hepatosplenomegaly, cardiological and respiratory impairments. It is the only MPS 
which is an X-linked disease. 
 In 1919, Dr. Gertrud Hurler, a Bavarian pediatrician discovered two patients in infancy 
who showed skeletal deformities, corneal clouding and cognitive impairment. The disease, 
then referred to as ‘Gargoylism’ is now known as MPS I [9]. Hurler syndrome (The severe 
clinical form of the disease) and Hunter syndrome share similar clinical features with the 
exception of corneal clouding, a feature only seen in the former. 
Scheie Syndrome is the comparatively attenuated form of MPS I, caused by one of 
several mutations which reduce, but do not completely inhibit the activity of IDUA. The 
symptoms include musculoskeletal abnormalities, corneal clouding and cardiorespiratory 
disease, though intellect and lifespan are normal. Both MPSs I and II store DS and HS in the 
lysosomes and are the more commonly diagnosed MPSs [10]. 
Dr. Sylvester Sanfilippo discovered MPS III [11], now known to have four different 
forms depending on the affected enzyme (IIIA, SGSH; IIIB, NAGLU; IIIC, HGSNT; IIID, 
GNS), with all resulting in HS storage but with substantially similar clinical severity. Patients 
with MPS III show a mild bone and joint disease, and pronounced neuropathology with 
cognitive decline.  
17 
 
It was in 1929 that the disease now known MPS IV was described independently by 
Morquio and Brailsford in Uruguay and England respectively. Its clinical features include 
corneal clouding, cardiac dysfunction, odontoid hypoplasia and bony lesions occurring 
because of a mutation in either the GALNS gene (for Galactosamine-6-sulfatase) with KS and 
CS storage or the GLB1 gene (for β-Galactosidase) with only KS storage. These forms are 
respectively called Morquio Syndrome A and B. MPS VI (Maroteaux-Lamy Syndrome) was 
first properly described as a deficiency in Arylsulfatase B (ARSB) activity by physicians Pierre 
Maroteaux and Maurice Lamy [12]. 
Patients are rarely affected cognitively, but their symptoms include corneal clouding, 
cardiac impairment, coarse facies, and short stature combined with dysostosis multiplex, 
consistent with the storage of DS. The rare deficiency of β-glucuronidase (GUSB) causes MPS 
VII (Sly syndrome), and was first described by William Sly in 1973 [13], in what was initially 
noted as a phenotype very similar to Hurler syndrome, with corneal clouding, coarse facies, 
dysostosis multiplex, hepatosplenomegaly, and short stature described in subsequent patients. 
There are varying levels of neuropathology and cognitive impairment. A unique aspect of Sly 
syndrome is the occasional evidence of hydrops fetalis in the severe phenotype. The deficient 
activity of GUSB causes the lysosomal storage of DS, HS and CS [2]. The rarest MPS 
diagnosed is hyaluronidase deficiency (HYAL1) which causes storage of HA, and was first 
characterized in 1996 by Natowicz et al. [14]. 
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Table 1.1.  A list of the Mucopolysaccharidoses, derived from Neufeld, Muenzer (2001) [2] 
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The classic approach to diagnosis of MPS disorders, relies on preliminary identification 
of visible symptoms followed by testing of urinary GAG levels as a biomarker, as all of the 
MPSs show high concentrations of GAGs in urine. Diagnosis is confirmed by enzyme activity 
assays to determine the specific MPS affecting the patient (some MPSs share the same storage 
products but as a result of different enzyme deficiencies, see Table 1.3). Efforts to diagnose 
these diseases now commonly include genetic testing, newborn screening and pre-natal 
screening in the case of parents with affected children. Early diagnosis is key to starting 
treatment, in order to ameliorate the manifestation of symptoms and prevent irreversible tissue 
damage. 
Treatment of MPS diseases 
There is no definitive cure for any of the mucopolysaccharidoses. Many endeavors are 
being undertaken to understand the full spectrum of these diseases and their characteristics. 
The root of an MPS disease is improper or insufficient degradation of GAGs, so one strategy 
is to reduce the burden of GAGs presented to the lysosomes. Another strategy is to repair the 
activity of the deficient enzyme. Development of therapies is largely dependent on animal 
models of MPS diseases, both large (e.g. canine, feline) and small (murine). The most 
commonly used treatments are enzyme replacement therapy (ERT) and hematopoietic stem 
cell transplantation (HSCT). The former is already in active use for MPS I, II and VI while an 
MPS VII therapy has been recently approved by the US FDA [15-21]. Use of intrathecally 
delivered recombinant NAGLU has shown promise in the treatment of MPS IIIB in animal 
models [22]. Hurler syndrome can be treated successfully by early HSCT (prior to 2.5 years of 
age), although this procedure is not without risk [23]. The major challenge in treating the 
neuropathological MPS diseases (I, II, III A, III B, III C, III D, VII) is the delivery of treatment 
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to the brain, as it is difficult for enzyme produced from transplanted stem cells or recombinant 
enzyme delivered intravenously to cross the blood-brain barrier. There is also the challenge of 
treating secondary immunological cascades that occur possibly as a result of 
neurodegeneration and the accumulation of GAGs and gangliosides in glial cells [24, 25]. 
These treatments aren’t sufficient to adequately prevent the manifestation of neurological 
symptoms. One strategy involves supplementing a normal copy of the defective gene so as to 
produce the required enzyme at an early age. That strategy is gene therapy. Several studies are 
underway involving the use of vectors such as adeno-associated virus (AAV) and zinc-finger 
nucleases (ZFNs) for delivering a normal copy of the gene [26-32]. 
Several biopharmaceutical companies are developing these strategies under the 
incentive of the US Orphan Drug Act of 1983. While some are still in pre-clinical development, 
others are already in clinical trial stages. In 2017, an MPS II patient with an attenuated 
phenotype became the first to receive a liver-directed ZFN-vector in vivo gene therapy 
developed by Sangamo therapeutics, a company that is also developing a similar treatment for 
MPS I.  Studies conducted on animal models of MPS using AAV vector also show promise 
and are under development for clinical trials [33]. 
Mucopolysaccharidosis Type I 
A mutation in the IDUA gene causes a deficiency in the activity of α-L-Iduronidase 
(EC 3.2.1.76) resulting in  the disease known as MPS I. Based on the functional impact of the 
mutation on the gene, the disease manifests on a spectrum of clinical severity diagnosed as 
Hurler Syndrome (I-H) (OMIM: 607014), Hurler-Scheie Syndrome (I-H/S) (OMIM: 607015) 
and Scheie Syndrome (I-S) (OMIM: 607016) [2]. 
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Molecular Genetics 
As is the case with most LSDs, MPS I follows an autosomal recessive Mendelian 
inheritance pattern. The variance in clinical severity seen is due to the type of disease-causing 
mutation in the IDUA gene, with over 55 identified to date. The IDUA locus has been mapped 
to the short arm of the 4th chromosome (4p16.3) [34-38]. While spontaneous mutations may 
occur, the disease is more frequently inherited as a compound of disease-causing alleles from 
carrier parents. The frequency of occurrence of each mutation also varies by geographical 
region and heritage across populations. For example, over 60% of patients of Caucasian 
descent with Hurler phenotype have the stop codon causing mutations W402X and/or Q70X. 
The P533R minor allele that is also commonly seen in the severe phenotype. However, these 
mutations are absent in Hurler patients from regions such as Japan or the Middle-East. The 
R89W mutation seen in attenuated phenotype patients from Japan greatly reduces (by about 
10-fold), but doesn’t fully inhibit IDUA activity. Phenotype severity depends on different pairs 
of mutant alleles present; for example, homozygosity of W402X or Q70X is clinically more 
severe than heterozygous combinations such as W402X/P533R and W402X/R89Q or even a 
homozygous P533R. However, it is difficult to clinically define all individual phenotypes into 
one of the three major categories as they occur on a full spectrum of severity [39, 40]. 
Clinical Pathology of MPS I 
Biochemical and histological features 
 Diagnosis of MPS I is primarily determined by urinary GAG analysis and 
confirmed by enzyme activity assay.  Heparan sulfate is predominantly present on the surface 
of cells or in the ECM in heparan sulfate proteoglycans (HSPGs). It is synthesized in the Golgi 
complex, as repeating heterodimeric units of glucosamine and D-glucuronic acid or L-iduronic 
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acid bonded by α 1→4 linkages. It is a diverse compound as it can undergo varying levels of 
sulfation or acetylation in the disaccharide units and may differ overall based on these levels. 
This allows for its adaptability in conformation resulting in different types of functions across 
cell and tissue systems, particularly as an intermediate in cell signaling pathways such as 
Wnt/Wg (a feature that has been studied in Drosophila). It undergoes a series of degradation 
steps, each catalyzed by different ubiquitous lysosomal enzymes as shown in figure 5: an 
acetyltransferase, glycosidases, and sulfatases. IDUA is a glycosidase that cleaves at the 
terminal iduronate residues of HS (an action it also performs in DS degradation), while 
glucuronic acid residues are cleaved by GUSB. The IDS, SGSH and GNS sulfatases each 
cleave specific terminal sulfated residues.  Diseases involving improper HS degradation all 
show neurodegeneration and gliosis in the CNS, implying that it is vital to neurological growth 
and development. DS is also a polysaccharide of heterodimeric repeats of N-
acetylgalactosamine and uronic acid (L-iduronic acid or glucuronic acid) with varying levels 
of sulfation as well. The enzymes ARSB, GUSB, IDS, IDUA, HEXA/HEXB are all involved 
in DS catabolism as depicted in figure 6.  The diseases which involve improper DS degradation 
occur as a result of a deficiency in any one of these enzymes and show common clinical 
features – hepatosplenomegaly, bone and joint abnormalities, or and (except in the case of 
MPS II) corneal clouding. This is consistent with the findings that it is an important component 
of cell signaling but with emphasis on connective tissue rather than the CNS. As with HS, DS 
is associated commonly as a part of its own proteoglycan system (DSPGs) which assembles 
the ECM and provides structural integrity to connective tissues [2, 41, 42]. 
Primary lysosomal storage of DS and HS is not only a feature of MPS I (MPSs II and 
VII store the same compounds but with different levels of sulfation or acetylation due to the 
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their unique enzyme deficiencies), but it is the most frequently diagnosed. Primary GAG 
accumulation occurs in multiple organs like the liver, spleen, kidney and joints – but a key 
focus is storage in the CNS of patients with Hurler syndrome. In fact, there are studies which 
have established post-mortem that GAG accumulation is about 1% of the dry weight of the 
brain in these patients. Storage is also noted in the CSF and leptomeninges, as high as 20-fold 
more than normal levels in patients with Hurler and Hunter syndromes [2]. 
 
Figure 1.4 Heparan sulfate degradation pathway, derived from King (1996) [1] 
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In addition to GAGs, there is also a secondary storage of lipids in the brain - GM2, 
GM3 and GD3 gangliosides, and unesterified cholesterol.  These levels are highest in white 
matter regions of the brain and quantitatively proportional to the clinical severity of the disease 
(even up to about 50% increase in concentration of brain ganglioside levels).  
What is of note however, is heterogeneity in the localization of stored substrate in the 
cells of the nervous system, characterized by different types of inclusion bodies in the 
cytoplasm – vacuoles masquerading as seemingly empty bodies under electron micrographs 
which contain excess GAG, and membranous lamellar stacks called ‘zebra bodies’, the latter 
also seen in gangliosidoses [43-48]. 
  
Figure 1.5 Dermatan sulfate degradation pathway, derived from King (1996) [1] 
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These structures are associated with impairment in vesicular trafficking leading to 
demyelination of axons and the formation ‘meganeurites’ (swelling of the axons at the region 
proximal to dendrites) in Purkinje cells of the cerebellum. The effect has been histologically 
observed to cause overall atrophy of the neurons leading to apoptotic neurodegeneration in 
patients with the severe phenotype. These neurological findings have been observed to a 
reasonable level of consistency in patients affected with MPS III – which shares with MPS I a 
primary storage of HS and a secondary storage of gangliosides [44-46, 48-51]. 
The neuropathology of Hurler syndrome is not only characterized by neuronal cell loss, 
but also the activation of astrocytes and microglia (immune cells associated with the nervous 
system), as GAG storage in their lysosomes can initiate neuroinflammation, a feature seen in 
other neuropathological LSDs. Animal models (murine in particular) are best used to study the 
immune signaling pathways which are activated in mucopolysaccharidoses. It is important to 
understand why such a response is invoked. One theory is that abnormal storage in the 
lysosomes of neurons leads to their malfunction likely due to impaired vesicular transport and 
thus causes degeneration or ‘injury’. It may be postulated that this causes the release of damage 
associated molecular patterns (DAMPs) as signals to elicit an immune response. Microglia (the 
macrophages of the CNS) are then recruited as a corrective response to the neurodegeneration. 
However, due to lysosomal storage in the microglia, what should be a self-induced negative 
feedback loop towards their activation, is impaired. This causes a progressive hypertrophy and 
aggregation of microglia (as well as astrocytes and on occasion, oligodendrocytes), a condition 
known as gliosis. It has been observed in IDUA knockout mice that perineuronal microglia are 
not only higher in number, but they contain different concentrations of partially or improperly 
degraded storage substrates in cytoplasmic inclusion bodies [52-54]. The indicator for this 
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differential accumulation is the concentration of GM3, which is not only a product of higher 
sialylated complex ganglioside catabolism but also an intermediate step in their anabolism. In 
neurons especially, through vesicular transport, they are amongst the many compounds which 
are expressed on cell membranes – accounting for structural integrity, cell-cell communication 
and receptor-ligand binding. This implies that the storage of GM3 in the microglia may not 
only be a consequence of their endogenous accumulation but also due to secondary absorption 
of gangliosides by phagocytosis of damaged neurons. In a murine model of MPS I, GM2 levels 
were excessive in the amygdala, thalamus, hypothalamus and the cortex of the cerebrum – a 
feature that is expected to be a contributor to the progression of the disease [52, 53, 55]. 
Another immunological consequence of lysosomal GAG burden may be an impairment 
of the organelle’s structural integrity, which causes flaws in the intracellular balance between 
H+ and Ca2+ ions between the lysosome and the cytoplasm. This leads to irregular pH changes 
in the lysosomes and negatively impacts the activity of lysosomal hydrolase enzymes, which 
may cause secondary accumulation products. These faulty cascades could cause the 
transcription of apoptotic factors which results in chronic inflammation [55]. The CNS 
pathology of MPS I may also be considered aggravated by the release of reactive oxygen 
species (ROS) which explains the high oxidative stress marker transcription levels (such as 
glutathione concentration) seen in patients with MPS I [56]. Brains from murine models of 
MPS I have shown an overall progressive increase with age in the levels of cytokines - MCP-
1, MIP-1α and IL-1α - indicatory of chronic inflammation by recruitment of macrophages and 
neutrophils. In turn, neurodegeneration and gliosis lead to errors in synaptic signaling, which 
could be a reason for cognitive impairment [24, 52, 53]. 
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Morphological observations 
The major clinical features of Hurler syndrome begin at an early age. They include 
progressive CNS disease and cognitive impairment, dysostosis multiplex, visual impairment, 
hepatosplenomegaly, cardiac and respiratory blockages, hearing loss, etc. Affected newborns 
usually appear normal, although there are occurrences of hernias in the umbilical region [2]. 
Central nervous system morphology 
Hurler syndrome exhibits progressive neuropathology and cognitive impairment. A 
consistent feature seen is an atrophied brain larger in size than that of an unaffected person. 
Neuroimaging studies and post-mortem surveys show enlarged perivascular spaces throughout 
the brain, notably in the corpus callosum, thalamus and the periventricular regions. 
Concurrently seen are stark lesions in the white matter regions across the anteroposterior area 
of the brain. The lateral ventricles, subarachnoid spaces and cortical sulci are all dilated and 
enlarged regions. It is understood that the progressive developmental impairment of the 
ventricular system in Hurler syndrome contributes or is at least associated with the high 
accumulation of cerebrospinal fluid (CSF) in the brain leading to hydrocephalus. These 
symptoms reach clinical severity in patients exhibiting the Hurler phenotype at an early age 
and result in death prior to the age of 20 if left untreated [57-60]. 
Bone and joint disease  
 
In decreasing order of severity from Hurler to Scheie phenotypes, MPS I patients show 
a progressive skeletal dysmorphia across the body – a condition known as a dysostosis 
multiplex. Stiffness of joints is observed across all phenotypes. While most Scheie patients 
exhibit mild carpal tunnel syndrome and a slight compression of the spinal cord, skeletal and 
joint abnormalities are much more progressive and widespread in Hurler, and with Hurler-
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Scheie patients to a varying clinical severity. They exhibit macroencephaly (enlarged skull) – 
a likely consequence of HS storage induced hydrocephalus and DS storage in the bones. The 
sella turcica – a cavity that houses the pituitary gland – is J-shaped in severe and intermediate 
phenotypes. The sutures of the skull – sagittal and lambdoid are abnormally shaped.  Spinal 
abnormalities include kyphosis of the lumbar vertebrae, scoliosis of the thoracic vertebrae and 
in some patients, incompletely developed odontoid. The pelvis, rib cage and limbs all show 
progressive dysmorphia. The MPSs which aberrantly store DS all show bone and joint 
abnormalities, but Hurler syndrome shows the most strikingly severe features of dysostosis 
multiplex which result in impaired movement and coordination [2, 61]. 
Cardiovascular and respiratory pathology 
GAG accumulation in the lysosomes of cardiac and respiratory systems causes 
abnormal thickening and obstruction in all phenotypes of MPS I.  Bicuspid valve thickening 
and subsequent narrowing of the lumen, coronary artery impairment, aortic blockage – all 
result in hypertension and can even in intermediate phenotypes it can lead to death as a 
consequence of cardiac arrest. Meanwhile, the respiratory system is weakened by high 
susceptibility to infection and obstructions in the trachea, swollen tonsils, tongue and larynx. 
This causes breathing, speech and sleeping impairments in affected individuals [2, 62]. 
Ophthalmic Pathology 
With the exception of MPS II (Hunter syndrome), all MPSs with lysosomal DS storage 
exhibit corneal clouding, an outstanding feature of all phenotypes of MPS I. It is indicatory of 
an overall progressive visual impairment due to atrophy in the optic system and cranial 
abnormalities. The optic nerve is found to be enlarged in several Hurler patients. All 
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phenotypes do exhibit retinopathy and to varying rates of progression and certain patients have 
also been reported to suffer from glaucoma [63, 64]. 
Cognitive and Behavioral Problems 
 Across Hurler patients, early cognitive development is normal. After 2 years of age 
there begins a steady age-associated decline in cognitive ability and a delay (and in some cases 
even complete absence) in the achievement of milestones.  There is also delay and impairment 
of psychomotor activity, which may be associated as a consequence of peripheral 
neuropathology and dysostosis multiplex. The nature and degree of this aspect of MPS I 
neuropathology is on a wide scale of variance across the slightly milder phenotypes on the 
clinical spectrum. Patients show relatively lower attention span and secondary psychological 
problems such as self-esteem issues, social isolation, clinical depression and abnormal sleep 
patterns, the latter of which is associated with the respiratory impairments of the disease [65, 
66]. 
Animal Models of MPS I 
Large and small animal models have been used to study MPS diseases, their pathology 
and progression as well as to develop treatment strategies in a more thorough, comprehensive 
fashion that cannot be ethically conducted on humans. These models arise as either a result of 
some spontaneous mutation that has then been carefully bred over time into colonies or 
generated by functional gene knockout. Each animal model may have its benefits and 
shortcomings, and it is important to choose the animal model based on time constraints, the 
type of study and of course, budget. With MPS diseases, the emphasis on animal model 
research cannot be stressed enough: they are rare diseases and most of them are autosomal 
recessive, so they require extensive breeding; they are progressive multisystem diseases, so 
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different animals must be set aside to be assessed for biochemistry, histology, behavior, etc., 
even when testing a therapeutic strategy. While disease progression and symptomatic 
appearance varies between these models and compared to humans, their pathophysiology is 
quite similar.  
Murine models are advantageous to study the molecular genetics, histology and 
biochemistry of the disease, as these features are comparable to human pathology. They are 
convenient because mice have a relatively much shorter lifespan, give birth in litters, can be in 
bred to a high consanguinity (although this is not an advantage if one wants to consider the 
impact of genetic variation on disease epidemiology as is in humans) and can be used to set up 
large breeding colonies to obtain data of statistical significance in better understanding MPS 
diseases. These models have also been used to test potential therapies and their effects on 
alleviating or halting disease pathology in the short term. On the other hand, the long-term 
impact of a treatment or combination of treatments on multiple organ systems at different time 
points to assess cognitive, behavioral, connective tissue and nervous system pathology is best 
studied in large animal models [67-69]. 
α-L-Iduronidase deficiency has been characterized in three types of models: canine, 
feline and murine. Haskins et al. first defined MPS I with differing clinical characteristics in 
domestic and Siamese cats [70, 71]. A more commonly used canine model was generated by 
Shull and Spellacy et al. from a female and two male Plott hounds, the first dogs to be clinically 
diagnosed with naturally occurring MPS I [72-75]; since then it has been the foundation for 
many neuropathological and somatic tissue system studies and in the development of therapies 
such as Aldurazyme™ for human patients.  
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Our focus is instead on two murine models of MPS I established through targeted 
disruption resulting in complete absence of Idua activity. The first, was generated by Clarke et 
al. as a knockout of exon 2 in the murine Idua gene. Visual symptoms include a steady 
progression of body dysmorphia, significant body condition and weight decline by 40-50 
weeks. The lifespan of these mice was quite varied however, between 25 and 85 weeks of age. 
Primary GAG storage and secondary GM2, GM3 accumulation in the brain was noticeable 
around this age. Purkinje cell abnormalities were evident in histopathological analysis at 19 
weeks, but actual loss developed much later. Overall, consistent with the severe phenotype in 
humans, a shorter lifespan due to progressive somatic and nervous system pathology was 
observed [68, 76]. 
A second mouse model was generated in the lab of Dr. Elizabeth Neufeld, a key figure 
in the research of MPS diseases. It was created by the same technique as the Clarke model, 
except that it is a highly inbred model owing to repeated backcrossing, with a similar pathology 
but a more consistent lifespan (50-70 weeks of age) compared to control mice (~3 years) [52]. 
These murine models have been used to study the neuropathology and connective tissue 
manifestations of MPS I, and testing individual as well as combinatorial therapeutic strategies 
– a strategy that is instrumental in developing and refining treatments to take to the clinical 
stage. 
Therapeutic Strategies for MPS I 
 It is clear that the pathology of MPS I is characterized by a progressive disorder of 
multiple organ systems as a result of accumulation of storage products in the lysosomes due to 
the deficiency of IDUA activity. One can categorize the effects into three categories – Brain 
and CNS disease, organomegaly and connective tissue disease, and secondary downstream 
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effects. There are three major therapeutic strategies to treat MPS I – restoration of enzyme 
activity, deprivation of the accumulating substrates to decrease lysosomal burden and 
amelioration of secondary immunological effects.  
These strategies may also have to complemented by surgeries, which commonly 
include shunting to treat communicating hydrocephalus and orthopedic operations to correct 
bone and joint abnormalities. The clinical symptoms vary in severity across a spectrum, so the 
appropriate treatment option must be chosen based on the degree of pathology. While the 
outcomes of treatments for the neuropathological MPS diseases has made significant progress 
in the last two decades, there still doesn’t exist a complete cure to completely halt all aspects 
of disease pathology.  
For Hurler patients, treating the CNS is by far the most difficult aspect of developing 
therapies because of the blood-brain barrier, which does not allow intravenous therapeutics to 
be efficiently delivered to the brain. Treatment also depends very heavily on early diagnosis 
of the disease, as bone dysmorphia and neurodegeneration that has once occurred, cannot be 
undone, meaning it must be prevented. Following are the major therapeutic strategies in active 
development for the treatment of the disease: 
Improvement Of α-L-Iduronidase Activity 
Hematopoietic stem cell transplantation (HSCT) 
 
First introduced for MPS I in the early 80s, bone marrow transplantation (BMT), later 
hematopoietic stem cell transplantation (HSCT) has been a staple treatment for Hurler patients 
ever since. It’s a risky procedure when one considers the variables involved: A viable source 
of stem cells (bone marrow, umbilical cord stem cells or peripheral blood cells from a suitable 
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donor), complete removal of the patient’s stem cells to be replaced by the donor cells and 
immunosuppression to ensure that the patient’s immune system doesn’t attack the donor cells. 
Because of all these risks, it is a treatment recommended only for the Hurler phenotype (milder 
phenotypes can be effectively treated at an early age onwards by ERT). The result is a suitable 
source of IDUA production by the white blood cells from the donor bone marrow which 
through the circulatory system, reaches somatic cells across the body. After about a year of the 
transplantation and immunosuppressive management of the incorporated donor cells, IDUA 
activity returns to normal levels in the leukocytes, reducing the accumulating GAGs in the 
somatic tissues. As stated earlier, Hurler syndrome patients reach peak in their cognition 
between 2 and 4 years of age, after which they suffer cognitive decline [77]. Depending on the 
age of transplant, degree of restoration of enzyme activity, existing clinical severity at the time 
of transplant, donor-host compatibility (measured by human leukocyte antigen or HLA levels 
and the extent of chimeric incorporation into host tissue, the rate of cognitive recovery differs. 
However, it is still slightly delayed compared to unaffected individuals. 
 In the long term, HSCT has been seen to diminish several aspects of the disease 
resulting in alleviation from cardiovascular and respiratory blockage, hepatosplenomegaly and 
prevention of hearing loss. It halts further cognitive decline to an extent, but only if the Hurler 
patient has been diagnosed and treated at an age before complete CNS development (< 2 years). 
Long-term assessment of Hurler patients treated very early with HSCT shows that patients no 
longer require a shunt for communicating hydrocephalus, periventricular abnormalities are not 
aggravated any further and GAG storage in the brain gradually reduces, ergo CNS damage is 
stymied. So far, patient follow-up consensus data shows that patients successfully treated by 
HSCT have an improved survival rate into the third decade of their lives. It is reasonable to 
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suggest that this is contributed to by the lack of cardiovascular and respiratory obstructions. 
Recovery also depends on the source of stem cells. The use of umbilical cord blood seems to 
have a more advantageous effect. It has been associated with a higher frequency of complete 
replacement of donor stem cell integration into the patient resulting in higher IDUA activity. 
Due to its easier availability, it can be used in the transplantation procedure soon after 
diagnosis. One cannot compare the overall benefit of umbilical cord stem cells over bone 
marrow because patients have been treated with the former more recently compared to the 
latter. In summary, HSCT can be used as a treatment option for Hurler patients, but it must be 
done as early as possible in order to avoid or at least minimize brain and somatic abnormalities. 
It remains however, a very risky procedure due to a high failure rate of transplantation, need 
for a perfect donor, clinical variability based on factors preceding transplantation, possible 
respiratory and cardiac complications and the capacity to drastically reduce the patient’s 
immunity at least during the period of engraftment [78-85]. 
Enzyme replacement therapy (ERT) 
As HSCT is a method of endogenously restoring enzyme activity, ERT is a strategy 
employed to restore the activity of IDUA in MPS I patients exogenously, having been in use 
for treatment since the turn of the century. The molecule used for treatment is Laronidase 
(Aldurazyme™) – a recombinant form of α-L-iduronidase, produced by recombinant DNA 
technology, which mimics the activity of the natural enzyme. The delivered enzyme expectedly 
makes its way into the lysosomes via uptake by mannose-6-phosphate receptor, thereby 
degrading DS and HS. Unlike HSCT which is highly risky and only preferred for Hurler 
patients, ERT is used as a therapy for all phenotypes of the disease. The currently approved 
delivery route is intravenous infusion of 0.58 mg drug/kg of body weight at regular intervals 
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and for individuals of all ages affected with MPS I [17, 86]. The effectivity of treatment on 
multiple organ systems depends on the age at which treatment is started as well as the clinical 
severity of the patient. As far as the treatment of Hurler-Scheie and Scheie phenotypes is 
concerned, it is quite effective in restoration of enzyme activity in the liver, reducing 
hepatosplenomegaly, respiratory obstructions and an overall halt in the progression of the 
disease. However, patients from the initial trials whom have now been treated for many years 
show that cardiovascular abnormalities do not uniformly subside, and neither is damage 
already done to the musculoskeletal system fully reversed. Urinary GAG levels do show 
significant decrease with a reasonable survival rate.  
The case with Hurler syndrome however, is much more complicated due to its severe 
and prevalent CNS pathology. Even high intravenous dosage of Laronidase does not 
sufficiently penetrate the blood-brain barrier well enough to ameliorate degeneration in the 
neuronal cells or the gliosis associated with CNS pathology. While it can certainly reduce GAG 
storage over time in somatic cells, it is not enough to fix damages to the heart valves and bone 
and joint abnormalities though it can prevent their further decline [86-88]. A study in a canine 
model of MPS I, wherein ERT was started at birth and continued on a weekly high dosage 
regimen up to as much as 81 weeks of age showed significant restoration of lysosomal activity 
across the ‘usual suspects’ major organ systems, bones and joints resulting in significant 
clinical recovery. Furthermore, of prime importance was the finding that a combined 
intravenous and intrathecal delivery of enzyme from birth was sufficient to prevent aberrant 
GAG storage even in the otherwise hard to reach CNS. Even though the dogs were treated with 
recombinant human α-L-iduronidase, they developed a tolerance to the enzyme – preventing 
an immune response. With the exception of ophthalmic pathology, a near complete prevention 
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in clinical pathology was observed in these dogs [89-91]. Such results are yet to be replicated 
in humans, with the major caveat being that the individuals that could possibly be treated from 
birth would need to have a family history of MPS I combined with a pre-natal diagnosis. Yet, 
it does provide some insight into the possible vitality of early, high-dosage treatment. ERT 
may be able effectively halt CNS pathology if it employs a chaperone that is accustomed to 
crossing the blood-brain barrier. Enter AGT-181 – a fusion molecule designed by Armagen© 
that comprises recombinant IDUA bound to a monoclonal antibody (mAb) designed to target 
the insulin receptor (IR), delivered intravenously. Pre-clinical studies in Idua-knockout mice 
showed complete clinical reversal of neuropathology. To test whether the fusion molecule 
could surpass the blood-brain barrier in primates, trials were performed on Rhesus monkeys to 
specifically test the extent of enzyme uptake in the brain. The results were conclusive: the 
fusion molecule was successfully transported to the brain, acting as a ‘Trojan horse’. The 
results of these pre-clinical trials have facilitated an active Phase 2 clinical trial of this therapy 
for Hurler patients [92-95]. 
Laronidase may also be used as a combination therapy with HSCT for treating Hurler 
patients diagnosed before the age of 2.5 years.  Due to the risks of secondary complications 
which may arise after HSCT such as pulmonary hemorrhage as a consequence of secondary 
pathogenic mechanisms, a combination of ERT and HSCT has been suggested for Hurler 
patients. In trials by Tolar et al. in 2007, patients were treated weekly with 0.58 mg/kg of 
laronidase for up to 14 weeks before and 8 weeks after transplantation. The results were quite 
positive – even though anti-IDUA antibodies were detected in the patients, it didn’t impact the 
transplantation procedure negatively, which is to say that that the antibodies did not neutralize 
post-transplant IDUA activity. Furthermore, the morbidity and occurrences of respiratory 
37 
 
complications were minimized and IDUA activity was normal. This implies that enzyme 
treatment before and after HSCT provided a consistent supply of IDUA to the cells, thereby 
leaving no room for systemic decline as a consequence of improper GAG degradation during 
the procedure while lowering the risk of future complications due to secondary pathogenic 
mechanisms as a result of grafting [23, 96]. Such a combination therapy of ERT with a 
consistent chemotherapy regimen associated with HSCT has the potential to better alleviate 
Hurler syndrome pathology.  
Gene Therapy 
 
The key concept behind restoring enzyme activity in the MPS disorders is ‘cross-
correction’ – the production of the required lysosomal enzyme by one cell type can result in 
its uptake by other cell types (through the mannose-6-phosphate moiety). It’s certainly a 
concept that works, as evidenced by HSCT where the replacement of leukocyte precursors 
restores enzyme activity across multiple organ systems [97]. As stated earlier however, HSCT 
is a procedure that is risky, life-threatening, highly dependent on the availability of a suitable 
donor and may cause donor-host cell immunoreactivity. This is where the need for gene 
therapy arises – to correct the faulty IDUA sequence by replacing it with a functional copy that 
restores enzyme activity in the host cells. Even for attenuated phenotypes I-H/S and I-S, ERT 
can be rather expensive as it must be administrated long-term at regular intervals, whereas a 
successful gene therapy would be a permanently corrective treatment.  Another potential use 
of gene therapy is to treat the ocular manifestation of MPS I. ERT at high dosage and HSCT 
are not enough to conclusively eliminate visual impairment due to corneal opacity, suggesting 
a relative inaccessibility of the eye through these avenues. Finally, CNS-directed therapies that 
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can completely restore neuronal cell GAG clearance are essential to preventing neuropathology 
of the disease [98, 99]. 
Delivery is an essential aspect of gene therapy, with two approaches: in vivo and ex 
vivo.  In vivo treatment entails the use of viral vectors (ex: AAV, lentivirus) or non-viral 
mechanisms like Zinc-finger nucleases, infused intravenously or intrathecally in to the patient. 
Several variants of AAV vectors have been approved in over 100 clinical trials for an 
assortment of diseases so far. One particular gene therapy currently in clinical trials is the use 
of AAV9-mediated gene editing using Zinc finger nucleases (ZFNs) to treat MPS patients – a 
liver directed therapy [27, 100]. 
Intracerebral delivery of AAV-vector-based gene therapy has been experimented in a 
canine model of MPS I (performed in conjunction with a canine model of MPS IIIB, another 
mucopolysaccharidosis with CNS disease manifestation). Vector incorporation and subsequent 
IDUA activity was observably widespread across the brain in treated dogs. Affected dogs that 
were administered this treatment adjunct with an immunosuppressive regimen at an early age 
(before manifestation of neuropathological symptoms) showed a marked attenuation in GAG 
and complex ganglioside storage in the brain compared to untreated affected dogs, though 
these levels were still higher than unaffected controls. Histological examination of the brain 
after euthanizing the treated dogs at ~8 months showed an overall reduction in cytoplasmic 
vacuolation, a consequence of improved substrate clearance. The major takeaway from this 
study is that AAV-vector-mediated delivery of IDUA to the CNS can significantly reduce 
neuropathological progression of MPS I, and that early treatment can induce a beneficial 
immune tolerance to the vector. [101, 102] Studies on murine models of MPS I involving viral 
vector gene therapy have shown vast improvement in mice treated at an early age, including a 
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particularly novel non-invasive method - nasal delivery of AAV9-mediated treatment, where 
treated mice showed full neurocognitive improvement at the age of 8 months [31, 103, 104]. 
These pre-clinical data exhibit an encouraging prospect for CNS-directed treatment by viral-
vector based gene therapy in MPS I patients, with efforts underway to proceed to the clinical 
trial stage. As of 2017, a Phase 1 clinical trial for liver-directed intravenous therapy of MPS I 
is underway, which employs AAV vector to deliver Zinc-finger nuclease (ZFN) mediated 
human IDUA gene therapy. ZFNs are genetically engineered restriction endonucleases which 
can target specific DNA sequences and cause double strand breaks resulting in mutagenesis. 
This particular therapy, also under trial for MPS II [105], targets the albumin locus in liver 
cells to allow for corrective production of functional IDUA.  
There are probable difficulties though, with the potential of the host developing 
immunoreactivity to viral vector-based therapy. Hence, non-viral approaches to gene editing 
are also being considered.  An example is a study involving the ‘Sleeping Beauty’ transposon 
(SB) system, a transgenic plasmid that uses an enzyme called a transposase to insert the gene 
of interest into the genome at a specific target. This system was used to introduce recombinant 
human IDUA into an immunodeficient Idua knockout mouse model, to assess its efficacy sans 
immunoreactivity to the expressed IDUA. This liver-directed therapy was able to restore 
enzyme activity resulting in complete somatic GAG clearance and correction of non-
neuropathological symptoms; a likely effect of cross-correction. Brain pathology was reduced 
to an extent but since immunodeficient mice have a short lifespan, it is difficult to gauge long-
term cognitive impact [106]. Comparatively however, viral vectors such as adenoviruses or 
retroviruses are highly preferential because of the efficiency in transduction and as mentioned 
earlier, the capability to restore enzyme activity over lifespan.  
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Most gene therapy studies are still in their pre-clinical stages and several have shown 
great promise in animal models. Efforts are being made to adapt these strategies for clinical 
trials as the benefits would outclass most other therapies – a non-life-threatening procedure 
with the potential for full reversal of neuropathology, bone and joint correction and alleviation 
of cardiovascular and respiratory symptoms leading to normal lifespan and cognitive 
capabilities.  
Substrate Deprivation Therapy 
 
 The principal stymie in treating MPS diseases accumulating DS and HS is in achieving 
the reversal of CNS and bone pathology. Substrate deprivation therapy focuses on inhibiting 
the synthesis of GAGs to prevent their accumulation, rather than restoring lysosomal enzyme 
activity. The current approach to meeting this goal is administration of drugs such as Genistein 
(a flavonoid) and Rhodamine B (a fluorone dye). These compounds have demonstrated 
phosphorylative inhibition of the epidermal growth factor receptor (EGFR) activity leading to 
a subsequent reduction in synthesis of GAGs while also contributing to their degradation. This 
finding along with the fact that an intrinsic characteristic of these compounds is their ability to 
cross the blood-brain barrier has prompted their testing on treatment of neuropathological MPS 
diseases. At a clinical stage, MPS III patients have exhibited recovery in neurocognition and 
GAG clearance when treated with a low dosage of genistein, but these results are not 
consistent. Rhodamine B treatment on mouse models of MPS I, II and III has shown 
amelioration of clinical symptoms with statistically significant GAG clearance in somatic cells, 
but only to a small extent in the brain [107-111]. 
Apart from these compounds, there is potential in the management of neuropathic MPS 
by standard issue non-steroidal anti-inflammatory drugs (NSAIDs) – such as 
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acetaminophen/paracetamol, nimesulide and indomethacin. These drugs are already FDA 
approved as anti-pyretics and analgesics, but tests performed on MPS fibroblast cultures 
indicate that they reduce the aggregate of sulfates in the cells - integral moieties in DS and HS. 
In addition, these drugs can also ameliorate neuroinflammatory signaling by inhibition of 
cyclooxygenase receptors (COX family). Furthermore, in vitro testing shows that a 
combination of low concentrations of genistein and NSAIDs is even more efficient in reducing 
the synthesis of GAGs [112]. An advantage of this treatment over rhodamine B is that substrate 
deprivation by treatment with NSAIDs is assuredly a safe method for at least partial if not 
complete amelioration of neuropathological symptoms because they have been in use for 
several years, albeit if not for treating MPS I. Hence, their safety and toxicity profiles are well 
defined and there is little danger of their causing side effects if administered at a low dosage.  
Management of Secondary Immune Responses 
 
 Most Hurler syndrome patients diagnosed before the age of 4 years are treated by 
HSCT and/or ERT. The treatment regimen often results in an immune response against donor 
graft or recombinant enzyme. For HSCT, a strong myeloablative cocktail of chemotherapy 
drugs which are designed to completely remove the patient’s existing immune cells and replace 
them thoroughly with that of a donor’s – a highly risky procedure. Enzyme replacement by 
laronidase produces an immune response by increase in IgG levels in most patients during their 
initial phase of treatment. Studies in MPS I dogs have shown that both enzyme replacement 
and gene therapy when introduced at birth allow the affected dogs to develop a tolerance to 
recombinant human IDUA [90]. We could reasonably assume then that to prevent an immune 
response to therapies, they must be introduced at the earliest stages of development. However, 
for those who have been diagnosed at a later stage, NSAIDs and corticosteroids be offered as 
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immune modulators. Other medications include those which are generally prescribed for bone 
and joint diseases such as rheumatoid arthritis. For example, a phase 1 clinical trial underway 
for treating MPSs I, II and VI involves the use of adalimumab (Humira®) – a TNF-α inhibitor 
to check if it can ameliorate stiffness of the joints and inhibit immune response [21, 113]. 
 Treatment of MPS I is no easy feat due to the number of challenges and the full 
spectrum of disease pathology. The emphasis is on early diagnosis and the emergence of new 
technology: one-time treatments such gene therapy leading to restoration of enzyme activity, 
timely stem cell transplantation supplemented by pre- and post-procedure ERT, and other 
combinatorial therapies. The aim is to cure the disease, so that affected children may actually 
recover to live full, healthy lives devoid of the burdens of a rare genetic disease.  
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CHAPTER 2: CHARACTERIZATION OF A MUCOPOLYSACCHARIDOSIS TYPE 
I AND GALNAC TRANSFERASE DEFICIENCY DOUBLE KNOCKOUT MOUSE 
 
Introduction 
 
The MPS are a group of inherited metabolic diseases caused by the genetically deficient 
activity of one of eleven enzymes responsible for the stepwise degradation of 
glycosaminoglycans (GAGs), leading to their storage in the lysosomes across multiple tissue 
and organ systems [2]. The most commonly diagnosed is MPS I, and is caused by the 
deficiency of α-L-Iduronidase (EC 3.2.1.76), resulting in the storage of dermatan sulfate (DS) 
and heparan sulfate (HS) in the lysosomes [6]. An autosomal recessive disease, MPS I is caused 
by a mutation in the IDUA gene (locus: HsA 4p16.3)[38]. Based on the mutation, IDUA 
activity may range from residual to null, leading to a spectrum of clinical severity. Although 
there are three diagnostically recognized syndromes of the disease [Hurler (MPS I-H, OMIM: 
607014), Hurler-Scheie (MPS I-H/S, OMIM: 607015) and Scheie (MPS I-S, OMIM: 607016)], 
it is in fact seen on a continuum from most severe (Hurler) to most attenuated (Scheie), with 
considerable possible overlap in signs and symptoms seen between the three syndromes. Hurler 
syndrome exhibits symptoms such as CNS disease leading to cognitive impairment, dysostosis 
multiplex, corneal clouding, hepatosplenomegaly, respiratory and cardiac abnormalities, and 
coarse facies. Death commonly occurs as a consequence of cardio-respiratory and orthopedic 
complications before adolescence. Scheie syndrome is typically characterized by bone and 
joint abnormalities, corneal clouding, cardiorespiratory disease, normal intellect and lifespan 
[2].  
Treatments are designed to address symptoms of the disease and restoration of enzyme 
activity. Compared to the attenuated forms, the major challenges associated with Hurler 
50 
 
syndrome treatment involve designing therapies that can cross the blood-brain barrier and 
effectively clear primary storage in the CNS before the damage is irreversible.   
Research using animal models has provided important contributions to our 
understanding of the pathophysiology of LSDs. The efficacy and safety of potential therapies 
have also been tested on these models. Canine, feline and murine models have been used to 
study MPS I. In dogs, the mutation is characterized by a G→A single nucleotide polymorphism 
at the donor splice site of the 1st intron in the IDUA gene, leading to a premature stop codon 
[114]. The typical signs and symptoms of this model are corneal clouding, bone and joint 
disease and cardiorespiratory abnormalities. Imaging studies have illustrated white matter 
abnormalities, cortical atrophy, ventriculomegaly, etc. This model has also been used to test 
bone marrow transplant, enzyme replacement and gene therapy strategies [73, 75, 115, 116]. 
The commonly used murine models of MPS I are the Clarke model (Iduatm1Clk) and the 
Neufeld model (Iduatm1Efn), each of which were generated by targeted gene knockout on a 
C57BL/6J background [52, 76]. Both models show severe bone and joint deformities, decline 
in motor coordination skills, cardiorespiratory disease and an overall decline in body condition. 
While Iduatm1Clk mice show a varied lifespan between 25 and 85 weeks of age, the Iduatm1Efn 
mice have an average lifespan of approximately 52 weeks (likely due to repeated 
backcrossing).  Biochemical and histological studies on Iduatm1Efn mice have shown lysosomal 
storage across multiple organ and tissue systems, as well as activation in inflammatory 
components of the CNS [52, 117].   
Gangliosides are sialylated glycosphingolipids (GSLs) which are abundant in the CNS. 
These molecules are located on external surface of the plasma membrane. They are 
metabolized by several enzymes, the deficiencies of which cause neuropathological, cognitive 
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and motor abnormalities. They are hence, suggested to be involved in the growth and 
development of the nervous system, though their specific role is not well understood [118, 
119]. In MPS I, the nervous system exhibits a secondary accumulation of complex gangliosides 
(particularly GM2, GM3 and GD3) and unesterified cholesterol – a feature of all 
neuropathological MPS diseases [68]. Walkley et al. (1988) observed the presence of 
meganeurites (axonal swellings) with and without spiny processes in human patients as well 
as in the canine model of MPS I, a feature also seen in the gangliosidoses AB variant, Tay-
Sachs and Sandhoff disease, which exhibit the primary storage of complex gangliosides [44]. 
The role of complex gangliosides in the nervous system has been studied in two mouse models, 
each lacking β-1,4-N-acetylgalactosaminyltransferase (officially designated as B4galnt1, 
henceforth referred to as GalNAcT), which synthesizes GM2 and GD2 from GM3 and GD3 
respectively [120, 121]. The GalNAcT knockout model used in our study (B4galnt1tm1Rlp)  
shows developmental delay in motor co-ordination, ataxia and neurological abnormalities such 
as reduced myelination of axons and neurodegeneration, identified at around 8 months of age. 
There is also a noticeable increase in neuroinflammatory activity, indicated by an increase in 
astrocyte and microglial activation. Their lifespan however, is normal when compared with 
wild type mice [120, 122]. Studies comparing WT and GalNAcT knockout mice have focused 
on investigating the role of complex gangliosides. Consensus shows that they play a role in the 
development and maintenance of the CNS. However, their role as a secondary accumulating 
product is not well understood.  
Treatment strategies for MPS I focus on cross-correction (cells which produce the 
required lysosomal enzyme will transfer it to deficient cells via the mannose-6-phosphate 
moiety) and substrate deprivation (reducing the synthesis of storage product would decrease 
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lysosomal burden) to ameliorate the disease. The latter has been explored in research on murine 
models of neuronopathic LSDs by generating double knockout mice (DKO) of the enzyme 
deficiency associated with primary storage and the enzyme associated with synthesis of the 
secondary accumulation product. In a study on a murine model of Sandhoff disease [Mutation 
in hexosaminidase β (Hexb) leading to primary storage of GSLs in the CNS], DKOs which 
inhibited GSL synthesis (GalNAcT(-/-)) and degradation (Hexb(-/-)) showed no primary storage, 
improved neuromotor skills and longer lifespan compared to Sandhoff SKOs [120].  
The nature of primary storage of unesterified cholesterol in Neimann-Pick Type C 
disease (Mutation in the membrane proteins Npc1 or Npc2) has been evaluated in DKO murine 
models. Unesterified cholesterol storage in both Npc1(-/-)GalNAcT(-/-) and Npc2(-/-)GalNAcT(-
/-)  DKO mice was reduced in the brain but significantly increased in other organs compared to 
SKO mice. Furthermore, these mice also had a shorter lifespan, indicating that it did not 
ameliorate clinical pathology [123-126].  A study involving double knockouts (DKOs) of 
GalNAcT deficiency and MPS IIIB and MPS IIIA (other neuropathological MPS diseases) 
found an accelerated clinical pathology in the absence of complex gangliosides leading to 
neuronopathic features such as Purkinje cell degeneration and white matter disease. The DKO 
mice also exhibited gait abnormalities, significant urine retention leading to shortened lifespan 
compared to single knockout (SKO) MPS IIIB and MPS IIIA mice. The DKO mice form a 
model that would allow us to better understand the neuropathological progression of the 
disease [127]. 
Our efforts sought to generate an overtly and clinically neuropathological model of 
MPS I, by obtaining Idua/GalNAcT DKOs to evaluate the disease. Our hypothesis is that a 
prospectively accelerated model similar to the those for MPS IIIA and MPS IIIB DKOs can be 
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used to evaluate CNS-directed therapeutic strategies. We obtained GalNAcT and Idua SKOs 
in order to develop the DKO model of MPS I, generating control mice used for comparison of 
clinical symptoms. Experimental animals were euthanized at humane end-points for the DKO 
mice with age-matched controls and fixed in paraformaldehyde solution for neurohistological 
analysis.  
Materials & Methods 
Experimental animals 
 In our experimental evaluation, we used MPS I (Iduatm1Efn) and GalNAcT 
(B4galnt1tm1Rlp) mice on a C57BL/6J background provided by Dr. Mark Sands (Washington 
University in St. Louis, MO) and  Dr. Ron Schnaar (Johns Hopkins University in Baltimore, 
MD) respectively.[52, 120] Normal mice supplied by Jackson Laboratory (Bar Harbor, ME). 
Mice were bred and maintained in a Laboratory Animal Resources colony according to 
Institutional Animal Care and Use Committee (IACUC) and Institutional Biosafety Committee 
(IBC) protocols approved by Iowa State University. A 12-hour light cycle with standard 
conditions of room temperature, pressure and humidity were maintained.  Breeding animals 
were set up in pairs with an Idua-null, GalNAcT heterozygous male and a double heterozygous 
female, or trios of 1 male and 2 females each double heterozygous at Idua and GalNAcT loci. 
One factor that influences this setup is that GalNAcT(-/-) males are found to be infertile.[120, 
128] While obtaining ideal breeding pairs i.e. Idua(-/-)GalNAcT(+/-) males and Idua(+/-
)GalNAcT(-/-) females is the long term goal in generating DKOs, SKOs and unaffected controls 
to a statistically significant number of experimental animals for analysis, double heterozygous 
trios or pairs were used in their absence.  
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Genotyping  
 
 Mice were toe-clipped to obtain DNA for genotyping by PCR. Extraction of DNA was 
performed by alkaline lysis of epithelial tissue.[129] The PCR employed a Bio-Rad© 
(Hercules, CA) thermocycler. The reaction profile for GalNAcT was 94°C (10 min), 98°C (30 
s) followed by 34 cycles at 98°C (10 s), 63°C (30 s) and 72°C (30 s).  For Idua, the reaction 
profile was  95°C (10 min), 98°C (10 s) followed by 40 cycles of 98°C (20 s), 65°C (60 s) and 
72°C (60 s). Both diagnoses included a final elongation step of 72°C (10 min) with a cooling 
step at 4°C. Reaction components included MgCl2 (2 mM), dNTP mix (each at 0.2 mM), Taq 
polymerase (GoTaq® Flexi, 0.5 units) 5X Taq buffer (Promega©) and template DNA (Idua - 
4 µl, GalNAcT – 2 µl). Primers were designed using the NCBI Primer BLAST tool (Table 
2.2). Amplified sequences were visualized on 2% gel electrophoresis using high gelling 
temperature agarose (Fischer Scientific) at 100V for approximately 1 hour. 
Table 2.1 Specifications of the primers used in PCR genotyping. f-forward primer, r - reverse 
primer 
Target Allele Primer Sequence 
Idua – WT and mutant (f) 5' GGAACTTTGAGACTTGGAATGAACCAG  3' 
Idua -WT (r) 5' CATTGTAAATAGGGGTATCCTTGAACTC 3' 
Idua – Mutant (r) 5' AATTCGCCAATGACAAGACG  3' 
GalNAcT – WT and mutant (f)  5' ACACGTGGAGCACTACTTCATG 3' 
GalNAcT – WT (r) 5' AGGTCCAGGGGCGTCTTCT 3' 
GalNAcT – Mutant (r) 5' TGCAATCCATCTTGTTCAATG 3' 
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Clinical observations 
  
Experimental animals were examined thrice weekly for clinical symptoms. They were 
observed for signs of skeletal and gait abnormalities, ataxia, tremors, body condition, urine 
retention and coat coarseness.  
Euthanasia and tissue processing 
 
Mice were euthanized at 20 weeks of age for histological analysis. Euthanasia was 
performed by an AVMA approved intracardiac perfusion protocol under full anesthesia. [130] 
Atropine (VetOne®, 0.054 mg/kg body weight) was subcutaneously administered as a pre-
anesthetic followed by intraperitoneal delivery of a Ketamine (VetOne®, 100mg/kg of body 
weight) and Xylazine (AnaSed®, 10 mg/kg of body weight) anesthetic cocktail. Upon reaching 
surgical plane of anesthesia, the body cavity was exposed followed by the rib cage, cutting 
through the diaphragm and removing any adipose tissue surrounding the heart. The heart was 
pierced with a butterfly catheter at the left ventricle apex, allowing the body to be flushed with 
10-15 ml of a 0.9% saline drip by nicking the right atrium. This was followed by fixing with 
4% PFA in phosphate-buffered saline (PBS). To allow the fixative to reach the brain, it was 
exposed by cranial dissection. The mice were then immersed in fixative and stored at 4°C for 
48 hours, following which they were placed in a PBS-storage buffer (with 0.05% sodium azide 
to prevent microbial contamination). Brain tissues were then sent for hematoxylin-eosin 
(H&E) staining.  
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Results 
Genotyping  
Two DKO mice and its age-matched SKO and unaffected controls were generated. 
PCR amplified sequences for each genotype are exhibited in figures 2.1 and 2.2. In each 
diagnosis, heterozygous animals showed two bands (one per allele). The WT and mutant bands 
for GalNAcT are approximately 596 bp and 300 bp respectively, while those for Idua are 520 
bp and 480 bp respectively. 
 
 
 
 
 
 
 
 
 
 
 
Clinical observations 
One DKO mouse died at the age of 16 weeks, likely an effect of starvation due to a 
malocclusion observed on death, a condition not uncommon in C57BL/6J mice. The other 
double knockout mouse started exhibiting its first clinical signs at as early as 15 weeks of age, 
which became more severe by the age of 20 weeks. At the time of euthanasia, it showed ataxia, 
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null 
 
 
WT  
null 
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null 
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null 
 
 
 
 
Figure 2.1 Idua PCR amplified sequences on 
a 2% agarose gel.  Lanes 1 through 3 show 
bands typical for carrier, affected and normal 
genotypes respectively. The bands are 
approximately 520 bp for the WT allele and 
480 bp for the null allele. 
 
Figure 2.2 GalNAcT PCR amplified 
sequences on a 2% agarose gel. Lanes 1 
through 3 show bands typical for carrier, 
affected and normal genotypes 
respectively. The bands are 
approximately 596 bp for the WT allele 
and 300 bp for the null allele. 
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slight kyphosis, dysmorphia of the hind limbs leading to poor gait, coarse coat, urine retention, 
tremors and a rectal prolapse. The Idua or GalNAcT SKO mice showed no noticeable 
symptoms at 20 weeks of age.    
Gross findings  
 
The DKO mouse upon dissection showed hepatosplenomegaly and urine retention, a 
distended gall bladder and swollen large intestine. In comparison, an age-matched Idua SKO 
showed mild hepatosplenomegaly. The DKO and Idua SKO mice showed a lack of adipose 
tissue surrounding the heart compared to the unaffected control. The GalNAcT SKO and 
unaffected mice were comparatively unremarkable upon gross examination.   
The visual symptoms of the DKO mouse at the time of its death are consistent with the 
typical pathology of an Idua SKO mouse at the end of its lifespan (approximately one year). 
One may postulate that the absence of Idua and GalNAc transferase activity causes an 
accelerated clinical progression of the disease as an impact of severely impaired lysosomal 
activity, leading to shorter lifespan. However, this is a preliminary finding from gross 
examination of the mice on dissection. The DKO showed overall increase in organomegaly 
which may have contributed to early death.  
On histological analysis with H&E staining, one may be able to ascertain the 
comparative extent of neuropathology between the DKO and SKOs. We may then be able to 
form a comparison between the results of DKO studies on other neuropathological MPSs and 
our model. 
  
58 
 
 
Figure 2.3 Gross findings of 20-week-old mice upon 
dissection. Top left: unaffected, top right: GalNAcT SKO, 
bottom left: Idua SKO, bottom right: Idua/GalNAcT 
DKO. The yellow arrows indicate organomegaly, while 
the green arrow indicates gall bladder distention and the 
blue arrow indicates urine retention 
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CHAPTER 3: CONCLUSIONS  
 
Our results indicate that a double knockout of GalNAcT and Idua leads to an 
accelerated disease and shortened lifespan. The exact mechanisms which lead to this outcome 
are still unclear. A previous study on other neuropathological MPS diseases involving MPS 
IIIA/GalNAcT and MPS IIIB/GalNAcT DKO mice showed accelerated progression, with a 
more pronounced neuropathology [127]. It is possible that in the DKO mice, a change in 
distribution of storage products occurs due to the absence of complex gangliosides, 
compounding the effect of primary storage. Studies on GalNAcT-null mice indicate that 
complex gangliosides play a role in axonal stability, yet they have a normal lifespan with slight 
neurodegenerative pathology. One may hypothesize that neuropathology in the DKO mice 
could be due to impairment of vesicular transport of gangliosides between the plasmalemma 
and the lysosomes, which leads to demyelination of axons [131-133]. Both the GalNAcT and 
Idua SKO mice have shown gliosis in previous studies [52, 134, 135]. It is possible that 
neurodegeneration caused by inflammation contributes to the accelerated pathology. We 
endeavored to create a DKO model in MPS I, which would better characterize the 
developmental defects in the brain and subsequent neurodegeneration as a potential impact of 
white matter disease. It is vital to generate more DKOs to verify the consistency of such 
findings. An extensive biochemical analysis on these mice would provide answers to the 
differential localization of storage products and whether that plays a role in the accelerated 
pathology. Development of this model may be useful in the rapid testing of therapies that focus 
on CNS-directed improvement of enzyme activity, and if are able to address the accelerated 
pathology, they would have a reasonable chance of providing maximum efficacy in treating 
human beings.  
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